01/21/2014
New Orleans—After at least a year of treatment with ibrutinib, more than 80% of patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) had a partial or complete response,...
New Orleans—After at least a year of treatment with ibrutinib, more than 80% of patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) had a partial or complete response,...
New Orleans—After at least a...
01/21/2014
First Report Managed Care